Skip to Main Content
PFF Help Center
(844) 825-5733
Facebook
LinkedIn
YouTube
Instagram
Join the PFF Registry
Donate
Shop PFF
Menu
Understanding PF
Newly Diagnosed: Start Here
PF Basics: Info for Newly Diagnosed Patients
About Pulmonary Fibrosis
What is Pulmonary Fibrosis?
Causes
Diagnosis
Symptoms
Glossary and Abbreviations
Types of Pulmonary Fibrosis
Idiopathic Pulmonary Fibrosis
Environmental
Occupational
Drug-Induced
Radiation-Induced
Autoimmune Connective Tissue Disease
Other Types of Pulmonary Fibrosis
Treatment Options
Supplemental Oxygen
Pulmonary Rehabilitation
Pulmonary Rehabilitation Toolkit
Symptom Management
Medication
Lung Transplantation
Patients & Caregivers
Medical and Support Resources
Find Medical Care
Find a Support Group
PFF Help Center
Pulmonary Rehabilitation Toolkit
For the Caregiver
Stories from the Heart
Clinical Trials
Medical Statements
Education Resources
Fact Sheets
Maintain Your Health
Videos
Webinars
Telemedicine
Educational Materials
Recursos de fibrosis pulmonar
PFF Insights Blog
Clinical Trials Blog
PFF Summit
Oxygen Therapy
What is Oxygen Therapy?
Benefits
Oxygen Rights and Resources
Oxygen Therapy FAQs
Join a Research Study
PFF Community Registry
APPLe Familial Pulmonary Fibrosis Study
PRECISIONS
Find a clinical trial
Researchers & Healthcare Providers
Clinical Resources
PFF Clinical Resource Hub
Webinars
CME/CE Library
Position Statements
Educational Materials
PFF Summit
Fact Sheets
Research Opportunities
PFF Community Registry
PFF Scholars and Other Research Opportunities
Familial Pulmonary Fibrosis Research Award
PROLIFIC
Community Engagement
Care Center Network
Nurse and Allied Health Network
Host an Event
Book a PFF Ambassador
Request Sponsorship Support
Ways to Give
Ways to Give
Workplace & Matching Giving
Planned Giving
Donor Advised Funds
Donate Stocks & Bonds
Qualified Charitable Distribution (QCD)
Donate Cryptocurrency
Donation FAQs
2026 Tax Law Changes
Albert Rose Legacy Society
Shop PFF
Honor and Memorial Giving
Make a Gift in Honor or Memory
Find a Tribute
Create a Tribute
Fundraising Events
PFF Walk
Broadway Belts for PFF!
Team PFF
Community Walk
Corporate Giving
Corporate Partners
PFF Corporate Committee
Donate Today
Mail-in Donations
Donate Monthly
Get Involved
Events
Attend an Event
Fundraise with Team PFF
Fundraising on Facebook
PFF Walk
PFF Summit 2025
Broadway Belts for PFF!
ILD Day
PFF Education Symposium
Let's Talk Cough
Volunteer
Join the PFF Community Registry
Start a Support Group
Be a PFF Advocate
Share Your Story
Become a PFF Ambassador
PF Awareness Month
Join a Board Committee
Shop PFF
PFF Walk
About the PFF Walk
Bay Area
Chicago
Dallas
National Walk Day
NYC Metro
Pittsburgh
Tampa
Washington, D.C.
Join the PFF Registry
What is the PFF Registry
Getting started
Submit a research proposal
History of the PFF Registry
Registry Report
Meet The Team
Sponsors
FAQ
About Us
Who We Are
Leadership
Mission & History
Medical Advisory Committees
Financials
Our 25 year anniversary
What We Do
The PFF is Me Strategic Plan
Patient Support Programs
Policy & Advocacy
PFF Funded Research
Education
News and Media
News
PFF In The Media
Breathe Bulletin
Media Resources
Careers
Contact Us
Search
Search
External News
Home
External News
PureTech Initiates Late-Stage Clinical Study of Wholly-Owned Candidate LYT-100 (Deupirfenidone) in IPF and Advances LYT-200 (Anti-Galectin-9 mAb)
July 05, 2022
Sandoz launches first generic pirfenidone in US for patients with idiopathic pulmonary fibrosis, growing its respiratory portfolio
June 13, 2022
Tvardi Therapeutics’ TTI-101 Receives Orphan Drug Designation for Idiopathic Pulmonary Fibrosis
May 31, 2022
Trevi Therapeutics Concludes Enrollment for Phase 2 CANAL Trial in IPF Chronic Cough
May 26, 2022
United Therapeutics Announces FDA Approval of Tyvaso DPI™
May 24, 2022
Vicore launches COMPANION, a clinical study investigating the benefit of digital therapy on anxiety in patients with idiopathic pulmonary fibrosis (IPF)
May 03, 2022
FibroGen Announces Completion of Patient Enrollment in ZEPHYRUS-1, a Phase 3 Clinical Study of Pamrevlumab in Idiopathic Pulmonary Fibrosis
May 03, 2022
Pliant Therapeutics Receives FDA Fast Track Designation for PLN-74809 for the Treatment of Idiopathic Pulmonary Fibrosis
May 03, 2022
aTyr Pharma Announces Positive End-of-Phase 2 Meeting with FDA on Efzofitimod for the Treatment of Pulmonary Sarcoidosis
March 22, 2022
OncoArendi Therapeutics Announces a License Option Agreement with University of Michigan
March 16, 2022
FDA Grants BI 1015550 Breakthrough Therapy Designation for Idiopathic Pulmonary Fibrosis
February 24, 2022
aTyr Pharma Advances Development of Lead Therapeutic Candidate ATYR1923 with Announcement of “efzofitimod” as Nonproprietary Name
February 17, 2022
Pliant Therapeutics Highlights Recent Developments for Lead Program PLN-74809 and Expected 2022 Milestones
January 25, 2022
Horizon Therapeutics plc Announces First Patient Enrolled in Phase 2b Pivotal Trial Evaluating HZN-825 for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)
January 25, 2022
Redx signs out licensing agreement with AstraZeneca
January 04, 2022
Pliant Therapeutics Reports Positive Interim Results from Phase 2a PET Imaging Clinical Trial in Patients with Idiopathic Pulmonary Fibrosis
September 08, 2021
NeRRe Therapeutics announces positive findings from Phase 2b study with orvepitant in chronic cough
August 04, 2021
Galecto Resumes Recruitment in Phase 2b Global GALACTIC-1 Trial of GB0139 for Idiopathic Pulmonary Fibrosis
July 20, 2021
FDA Approves New Use of Transplant Drug Based on Real-World Evidence
July 19, 2021
aTyr Pharma Announces Last Patient Visit in Phase 1b/2a Clinical Trial of ATYR1923 in Patients with Pulmonary Sarcoidosis
July 15, 2021
1
2
3
4
5
6
7
8
9
